NCT06219733View on ClinicalTrials.gov

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 1, 2021

Primary Completion Date

May 23, 2022

Study Completion Date

May 23, 2022

Conditions

Dermoid

Interventions

DRUG

Vactosertib

200 mg PO BID 5 days on / 2 days off

DRUG

Imatinib

Imatinib 400 mg PO QD daily

Trial Locations (1)

Unknown

Yeonsei University Severance Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

MedPacto, Inc.

INDUSTRY